Sort
10,766 grants matching “checkpoint inhibitor”
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
$480,846Barbara Burtness · Yale University · P50 · FY2023 · DE
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
$480,833Steffan T Nawrocki · University Of Arizona · R01 · FY2025 · CA
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
$480,833Steffan T Nawrocki · University Of Arizona · R01 · FY2022 · CA
A novel strategy to overcome drug resistance in cancer
$480,820Aimee L Edinger · University Of California-Irvine · R01 · FY2023 · CA
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
$480,760Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2023 · CA
SMART ASSAYS FOR LIGANDS TO STUDY AND TREAT CANCER
$480,736Harvard University (Medical School) · P01 · FY2000 · CA
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors
$480,710Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2022 · CA
Next-Generation Antibody Discovery and Development Technology
$480,577David Scott Johnson · Gigagen, Inc. · R44 · FY2017 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$480,413Xin Chen · University Of Hawaii At Manoa · R01 · FY2023 · CA
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$480,412Alexander H. Stegh · Washington University · R01 · FY2025 · NS
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$480,259Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Defining the role of NF1 and SPRED1 loss in melanoma
$480,247Iwei Yeh · University Of California, San Francisco · R37 · FY2024 · CA
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
$480,188Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2025 · CA
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy
$480,131Li Ma · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Targeting the LIFR-LCN2 pathway to improve liver cancer therapy
$480,131Li Ma · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Solid Phase Microextraction as a New Tool for Quantifying Antibody Drugs in Breast Cancer and Building PK-PD models
$480,000Florin Marcel Musteata · Albany College Of Pharmacy · R15 · FY2024 · CA
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
$479,806Andrew J. Gentles · Stanford University · U01 · FY2024 · CA
Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
$479,662Marikki Laiho · Johns Hopkins University · R01 · FY2019 · GM
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$479,648Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
$479,517Marikki Laiho · Johns Hopkins University · R01 · FY2020 · GM
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
$479,492Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Drug Mechanism of Action-based targeting of tumor subpopulations
$479,435Andrea Califano · Columbia University Health Sciences · U54 · FY2023 · CA
Eukaryotic Chromosome Replication
$479,430Bonita J Brewer · University Of Washington · R01 · FY2007 · GM
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$479,380Jerry D Glickson · University Of Pennsylvania · R01 · FY2021 · CA
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
$479,376Jennifer Temel · Massachusetts General Hospital · R01 · FY2020 · CA